Small-molecule inhibitors/modulators of amyloid-β peptide aggregation and toxicity for the treatment of Alzheimer's disease: a patent review (2010 – 2012)

Genetic, physiological, and biochemical data indicate that agglomerates of the 42-amino acid form of the amyloid-b (Ab42) peptide are strongly linked to Alzheimer’s disease (AD) etiology and thus represent a particularly attractive target for the development of an effective diseasemodifying approach for AD treatment. A plethora of chemical entities able to modulate Ab42 self-assembly have been developed in recent years, among them, several are in clinical or preclinical development.